Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 133

1.

Prospects and challenges for immunotherapy of ovarian cancer--what can we learn from the tumor microenvironment?

Chiriva-Internati M, Cobos E, Cannon MJ.

Int Rev Immunol. 2011 Apr-Jun;30(2-3):67-70. doi: 10.3109/08830185.2011.571731.

PMID:
21557634
2.

The immunotherapy of patients with ovarian cancer.

Hwu P, Freedman RS.

J Immunother. 2002 May-Jun;25(3):189-201. Review.

PMID:
12000860
3.

Sperm protein 17: clinical relevance of a cancer/testis antigen, from contraception to cancer immunotherapy, and beyond.

Chiriva-Internati M.

Int Rev Immunol. 2011 Apr-Jun;30(2-3):138-49. doi: 10.3109/08830185.2011.569903. Review.

PMID:
21557640
4.

Understanding the cross-talk between ovarian tumors and immune cells: mechanisms for effective immunotherapies.

Chiriva-Internati M, Mirandola L, Kast WM, Jenkins MR, Cobos E, Cannon MJ.

Int Rev Immunol. 2011 Apr-Jun;30(2-3):71-86. doi: 10.3109/08830185.2011.561507. Review.

PMID:
21557635
5.

TRANCE- and CD40 ligand-matured dendritic cells reveal MHC class I-restricted T cells specific for autologous tumor in late-stage ovarian cancer patients.

Schlienger K, Chu CS, Woo EY, Rivers PM, Toll AJ, Hudson B, Maus MV, Riley JL, Choi Y, Coukos G, Kaiser LR, Rubin SC, Levine BL, Carroll RG, June CH.

Clin Cancer Res. 2003 Apr;9(4):1517-27.

6.

Immunological treatment of ovarian cancer.

Cannon MJ, Santin AD, O'Brien TJ.

Curr Opin Obstet Gynecol. 2004 Feb;16(1):87-92. Review.

PMID:
15128013
7.

Immunologic approaches to ovarian cancer treatment.

Sabbatini P, Odunsi K.

J Clin Oncol. 2007 Jul 10;25(20):2884-93. Review.

PMID:
17617519
8.

Ovarian cancer creates a suppressive microenvironment to escape immune elimination.

Yigit R, Massuger LF, Figdor CG, Torensma R.

Gynecol Oncol. 2010 May;117(2):366-72. doi: 10.1016/j.ygyno.2010.01.019. Epub 2010 Feb 9. Review.

PMID:
20144842
9.

Novel immunotherapeutic strategies in gynecologic oncology. Dendritic cell-based immunotherapy for ovarian cancer.

Santin AD, Bellone S, Underwood LJ, O'Brien TJ, Ravaggi A, Pecorelli S, Cannon MJ.

Minerva Ginecol. 2002 Apr;54(2):133-44. Review.

PMID:
12032451
10.

Harnessing the immune system for ovarian cancer therapy.

Odunsi K, Sabbatini P.

Am J Reprod Immunol. 2008 Jan;59(1):62-74. Review.

PMID:
18154597
11.

Novel target antigens for dendritic cell-based immunotherapy against ovarian cancer.

Cannon MJ, O'Brien TJ, Underwood LJ, Crew MD, Bondurant KL, Santin AD.

Expert Rev Anticancer Ther. 2002 Feb;2(1):97-105. Review.

PMID:
12113075
12.

Sperm protein 17 is a suitable target for adoptive T-cell-based immunotherapy in human ovarian cancer.

Chiriva-Internati M, Weidanz JA, Yu Y, Frezza EE, Jenkins MR, Kennedy RC, Cobos E, Kast WM.

J Immunother. 2008 Oct;31(8):693-703. doi: 10.1097/CJI.0b013e31818283d5.

PMID:
18779750
13.

Antitumor vaccination: where we stand.

Bocchia M, Bronte V, Colombo MP, De Vincentiis A, Di Nicola M, Forni G, Lanata L, Lemoli RM, Massaia M, Rondelli D, Zanon P, Tura S.

Haematologica. 2000 Nov;85(11):1172-206. Review.

14.

Ovarian cancer immunotherapy: opportunities, progresses and challenges.

Liu B, Nash J, Runowicz C, Swede H, Stevens R, Li Z.

J Hematol Oncol. 2010 Feb 10;3:7. doi: 10.1186/1756-8722-3-7. Review.

15.

Tumor antigens and markers for breast and ovarian cancers.

Ghadersohi A, Chitta K, Greco WR, Harvey S, Winston J, Slocum H, Odunsi K, Sood AK.

Front Biosci. 2002 Feb 1;7:e48-57. Review.

PMID:
11815284
16.

Recent advances in cancer immunotherapy with an emphasis on vaccines.

Cavallo F, Forni G.

Expert Rev Vaccines. 2009 Jan;8(1):25-8. doi: 10.1586/14760584.8.1.25.

PMID:
19093768
17.

Dendritic cells in cancer vaccines.

Brossart P, Wirths S, Brugger W, Kanz L.

Exp Hematol. 2001 Nov;29(11):1247-55. Review.

PMID:
11698120
18.

Immune therapy for ovarian cancer: promise and pitfalls.

Thibodeaux SR, Curiel TJ.

Int Rev Immunol. 2011 Apr-Jun;30(2-3):102-19. doi: 10.3109/08830185.2011.567361. Review.

PMID:
21557637
19.
20.

[Monoclonal anti-idiotype antibodies in immunotherapy of ovarian carcinoma (MAb ACA125) and breast carcinoma (MAb ACA14C5)].

Wagner U, Köhler S, Prietl G, Giffels P, Schmidt-Nicolai S, Schlebusch H, Grünn U, Bender H, Biersack HJ, De Potter C, Krebs D, Wallwiener D.

Zentralbl Gynakol. 1999;121(4):190-5. Review. German.

PMID:
10355096

Supplemental Content

Support Center